Purchase Order 75N93018P00856

The Food and Drug Administration awarded a $20,745.32 firm fixed-price purchase order to Genscript USA Inc. on July 21, 2020, for monoclonal antibody production services. The contract, designated as a partial small business set-aside, is scheduled for completion by July 31, 2021, with work performed at Genscript's facility in Piscataway, New Jersey. Genscript USA Inc. is a biotechnology company specializing in advanced molecular biology services, including gene synthesis, protein production, and...

This is a Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey. The contract is for the provision of monoclonal antibody (mAb) development services, with a completion date of September 19, 2025, and a ceiling value of $13,062.24. The contract does not have a set-aside designation. Genscript USA Inc. is a for-profit organization that specializes in advanced...

The U.S. government awarded a purchase order valued at $5,075.85 to Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey, for monoclonal antibody products. The contract, awarded on September 19, 2016, with an ultimate completion date of March 20, 2017, was issued under a firm fixed-price pricing structure by a civilian federal agency (Southeast Area). No set-aside designation was applied to this award. The place of performance is located in Piscataway, New...

The U.S. Food and Drug Administration (FDA) awarded an $272.4K firm fixed-price purchase order to Antibody Solutions for the production of monoclonal antibodies production clones. The contract, designated as a Total Small Business set-aside, was awarded on August 1, 2024, with an ultimate completion date of July 31, 2029. Performance will take place at the contractor's facility in Santa Clara, California. This procurement supports the FDA's regulatory and scientific mission, as monoclonal...

The National Institute of Standards and Technology awarded a purchase order to Sigma-Aldrich, Inc. for manufacturing monoclonal antibody expressed from the NISTCHO cell on February 5, 2025, with a ceiling value of $500,000.00 and firm fixed-price terms. Performance is located in Great Britain, United Kingdom. The requirement involves development and scale-up of upstream and downstream processes to produce 1–5 kilograms of monoclonal antibody reference material from a single bioreactor run,...

Genscript USA Inc. was awarded a $54,900 firm-fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to provide customized antibody and plasmid preparation services. The award is associated with a pre-solicitation notice indicating the NIAID's intent to negotiate on a sole-source basis with Genscript for 100 customized antibodies and 200 plasmid preparations to support identification of...

The National Institutes of Health National Institute of Allergy and Infectious Diseases (NIH NIAID) awarded a $59,541 firm fixed price purchase order to Genscript USA Inc. to provide customized antibody synthesis, expression, purification, and plasmid preparations in support of the Laboratory of Malaria Immunology and Vaccinology's (LMIV) malaria vaccine research. Per the original solicitation, LMIV requires custom monoclonal antibodies that can label and sort immune cell subsets in its colony...

This is a firm-fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to A&G Pharmaceutical, Inc. (doing business as Precision Antibody). The contract is for the preparation of monoclonal antibodies against the MARCH1 protein, with a ceiling value of $16,900.00 and a performance period through July 31, 2025. A&G Pharmaceutical is a for-profit manufacturer of biological...

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $33,560 purchase order to Antibodies Incorporated for two monoclonal antibody projects. Antibodies Incorporated, doing business as Antibodies Inc., will deliver the requested monoclonal antibodies from its Bethesda, Maryland facility within the one-month period of performance ending September 30, 2023. As the prime contractor, Antibodies Inc. will be responsible for completion of the two...

The U.S. government awarded a $5,126.85 firm fixed price purchase order to Genscript USA Inc. for monoexpress basic antibody service. The contract was awarded on May 11, 2017, with an ultimate completion date of November 11, 2017, and does not utilize a set-aside designation. The place of performance is New Orleans, Louisiana, and the funding originates from a civilian federal agency within the Southeast Area. Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey,...